HOME >> MEDICINE >> NEWS
International study highlights underuse of reperfusion therapy for heart-attack patients

N.B. Please note that if you are outside North America the embargo time for Lancet Press Material is 0001 hours UK Time Friday 1st February 2002.

Up to a third of patients with a severe heart attack may not be receiving reperfusion therapy, despite the well-known benefits of this treatment strategy, conclude authors of an international study in this weeks issue of THE LANCET.

The benefits of reperfusion therapy- the use of fibrinolytic agents and/or coronary angioplasty to restore coronary artery bloodflow -for patients with acute coronary syndromes have been established, but there is variation in the type of reperfusion given and in decisions about which patients are eligible for such therapy. Kim Eagle from the University of Michigan Medical Center, USA, and colleagues assessed current practices in relation to reperfusion therapy in patients with a specific heart-attack profile called ST-segment-elevation myocardial infarction using data from the multinational, prospective Global Registry of Acute Coronary Events (GRACE). This registry includes data for patients with acute coronary syndromes from 94 hospitals in 14 countries.

The investigators assessed data of the first 9251 patients enrolled in GRACE; of these, 1763 presented within 12 hours of symptom onset with ST-segment-elevation myocardial infarction, 30% of whom did not receive reperfusion therapy. Elderly patients (75 years and older), those presenting without chest pain, and those with a history of diabetes, congestive heart failure, myocardial infarction, or coronary bypass surgery were less likely to receive reperfusion therapy. The rate of primary percutaneous coronary intervention was highest in the USA (17%) and lowest in Australia, New Zealand, and Canada (1%). The rate at sites with a catheterisation laboratory was 19%.

Kim Eagle comments: A substantial proportion of patients who are eligible for reperfusion therapy still do not receive this treatment.
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7611-4076
Lancet
31-Jan-2002


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. National Academies advisory: May 2 Symposium on International Science Policy
3. Awards & fellowships at the International & American Association for Dental Research General Session
4. Lectures, keynoters, symposia highlight International Dental Research meeting
5. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
6. International gathering of experts to share retinoblastoma breakthroughs
7. International trial of two microbicides begins
8. International gathering at UH examines top computer code
9. International trial finds benefits of breast MRI in women at high risk
10. International study provides culture-by-culture clues to family violence and abuse
11. St. Jude scientist wins International Society of Experimental Hematology award

Post Your Comments:
(Date:10/31/2014)... 31, 2014 At the start of ... narrowly escaping carbon monoxide poisoning in their homes. Now, ... away, one family-owned, Missouri-based heating and cooling company is ... sure families start the home heating season with the ... , Beginning Nov. 1, 2014, E and Q ...
(Date:10/31/2014)... UT (PRWEB) October 31, 2014 ... new Activz Silver line offering natural silver ... wipes. For over a century, silver has been used ... in Activz Silver products is the most advanced version ... has a unique chemical structure that supports the existing ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... News) -- Obesity increases the risk of certain types ... two new U.S. studies show. One study of ... obese increased the risk for estrogen receptor-negative and progesterone ... this for a long time for white women, but ... study author Esther John, a senior research scientist at ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... , October 31, 2014 Multigate Medical ... patents of B. Braun Melsungen AG (B. Braun) by selling ... safety IV catheters manufactured by Poly Medicure Ltd (Polymed). The ... proceeding number VID 463 of 2013 can be ... detailed judgment, Multigate was found to have infringed claim 1 ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
Cached News: